ConductScience.org, home

Comparison · NCT02173379-5f5ca7d2

Absorb BVS vs XIENCE: Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Absorb BVS vs XIENCE: Number of Participants With Acute Success- Procedural Success (Subject Level Analysis). Trial comparisons, record NCT02173379-5f5ca7d2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02173379-5f5ca7d2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9310.9160.944wilson
Risk in group 20.9560.9440.966wilson
Risk difference, group 1 minus group 2-0.0249-0.043-0.00715newcombe hybrid score
Risk ratio, group 1 over group 20.9740.9560.993log
Odds ratio, group 1 over group 20.6210.4410.874log
Number needed to treat, for one fewer participant with the outcome on Absorb BVS than on XIENCE40.223.3140from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Absorb BVSSubjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System1,1941,282OG000
Group 2XIENCESubjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)1,2461,303OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)
Description
Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).
Time frame
In-hospital (≤ 7days)
Population
ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Source ClinicalTrials.gov

Trial

Title
Absorb IV Randomized Controlled Trial
NCT number
NCT02173379
Phases
NA
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Lead sponsor
Abbott Medical Devices
Results first posted
2018-07-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02173379-5f5ca7d2